GLP-1 Receptor Agonist Research: A Primer on GLP1-S, GLP2-T, and GLP3-RT

The glucagon-like peptide (GLP) family of receptor agonists has become one of the most active areas of metabolic and obesity research over the past decade. For laboratories investigating incretin pharmacology, energy homeostasis, and beta-cell biology, research-grade GLP receptor agonist peptides are an essential class of reagents. This article provides a research-focused primer on the GLP family and the three classes of GLP receptor agonist material available from Neo Labs: GLP1-S (mono-agonist), GLP2-T (dual GLP-1 / GIP agonist), and GLP3-RT (triple GLP-1 / GIP / glucagon agonist).

The Incretin Pathway

The incretin effect refers to the observation that nutrient delivery via the gastrointestinal tract produces a substantially larger insulin response than equivalent intravenous nutrient delivery. Pre-clinical research has identified glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as the principal incretin hormones responsible for this effect. Both are released from intestinal enteroendocrine cells in response to luminal nutrients and act through dedicated class B G-protein-coupled receptors expressed on pancreatic beta cells and, as ongoing research has revealed, on a wide range of additional tissues including brain, adipose, cardiac muscle, and bone.

Endogenous GLP-1 has a very short half-life in circulation due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Research-grade GLP receptor agonist peptides used in pre-clinical work are typically engineered analogs with resistance to DPP-4 cleavage, which permits the longer in vivo exposure windows needed for chronic dosing studies in rodents and non-human primates.

GLP1-S: Research on Selective GLP-1 Receptor Agonism

GLP1-S is a research-grade peptide that acts as a selective agonist at the GLP-1 receptor. Pre-clinical research with selective GLP-1 receptor agonists has explored a broad set of endpoints:

• Insulin secretion in glucose-stimulated isolated islet preparations and INS-1 / MIN6 beta-cell lines
• Body weight and food intake in diet-induced-obese (DIO) rodent models
• Gastric emptying and gastrointestinal motility in pre-clinical models
• Hepatic steatosis endpoints in models of metabolic dysfunction-associated steatotic liver disease (MASLD)
• Cardiovascular endpoints in rodent models of cardiac stress and atherosclerosis
• Neuroscience research, including reward circuitry and cognitive endpoints in rodent paradigms

The breadth of the published literature has made GLP-1 receptor agonist research one of the most active areas of pre-clinical investigation. GLP1-S is supplied as research-grade material; see the GLP1-S 10 mg product page for the current lot's third-party COA.

GLP2-T: Research on Dual GLP-1 / GIP Receptor Agonism

GLP2-T is a dual incretin receptor agonist peptide that activates both the GLP-1 and GIP receptors. Pre-clinical interest in dual agonism stems from the observation that GIP receptor activation in adipose tissue, originally seen as a barrier to obesity research, may produce favorable metabolic endpoints when combined with concurrent GLP-1 receptor activation in central nervous system feeding circuits.

Research with dual agonists has focused on:

• Comparative effect on body weight, body composition, and food intake versus selective GLP-1 receptor agonism in DIO rodents
• Insulin sensitivity, hepatic glucose output, and adipose tissue endpoints in models of type 2 diabetes
• Bone and skeletal endpoints, given GIP receptor expression in osteoblasts
• Cardiovascular endpoints in rodent and non-human primate work

Dual-agonist pre-clinical findings have generally reported larger effect sizes on weight-related endpoints than selective GLP-1 receptor agonism, motivating sustained research interest. GLP2-T is available for research use; see the GLP2-T 15 mg product page.

GLP3-RT: Research on Triple GLP-1 / GIP / Glucagon Receptor Agonism

GLP3-RT is a triple agonist peptide that activates the GLP-1, GIP, and glucagon receptors. Glucagon receptor activation, intuitively counterintuitive given glucagon's role in raising blood glucose, contributes in pre-clinical models to increased energy expenditure and lipolysis. The hypothesis underlying triple-agonist research is that the GLP-1 component of the pharmacology can offset the glycemic effect of glucagon receptor activation while the glucagon and GIP components contribute to enhanced metabolic effects.

Published pre-clinical findings have reported:

• Greater reductions in body weight in DIO rodent models compared with dual and selective GLP-1 receptor agonism
• Favorable changes in lipid profile and adipose tissue endpoints
• Effects on energy expenditure as measured by indirect calorimetry
• Hepatic endpoints in MASLD models, with research interest in the glucagon receptor's role in hepatic lipid handling

GLP3-RT is available in 10 mg and 30 mg research-grade material; see the GLP3-RT 10 mg and GLP3-RT 30 mg product pages for the current lot COAs.

Laboratory Handling Considerations

Lyophilized Form and Reconstitution

All GLP receptor agonist peptides in the Neo Labs catalog are supplied as lyophilized white powder. For research use, reconstitution with bacteriostatic water or sterile water for irrigation is standard. Reconstitution concentration is dictated by the research protocol. Working solutions are generally stored at 2–8°C and used within a defined window. Stock material in lyophilized form, stored at -20°C, is generally reported to retain integrity for extended periods.

Bacteriostatic Water

Bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative) is the most commonly reported reconstitution solvent in pre-clinical methods sections. It is available alongside the peptide material; see the bacteriostatic water product page.

Purity and Identity Verification

Research-grade GLP receptor agonist peptides should be supplied with a lot-specific Certificate of Analysis demonstrating peptide purity by reversed-phase HPLC, identity confirmation by mass spectrometry, and endotoxin assessment by LAL. Each peptide in the Neo Labs GLP receptor agonist catalog ships with a third-party COA from Kovera Labs, available on the product page.

Comparative Research Across the GLP Receptor Family

For research groups designing comparative studies across mono, dual, and triple agonist peptides, key considerations include matching pharmacokinetic exposure rather than absolute dose, accounting for species-specific receptor pharmacology (rodent vs. primate vs. human receptor sequences), and standardizing administration timing relative to feeding paradigms. Published comparative work, particularly in DIO rodent models, has generally reported a hierarchy of effect on body weight endpoints with triple-agonist > dual-agonist > selective GLP-1 receptor agonist, though the magnitude depends substantially on dose, model, and study duration.

Research Use Disclaimer

The information above summarizes published pre-clinical research on the GLP receptor agonist family. The peptides referenced are not approved by the U.S. Food and Drug Administration for any therapeutic indication. Materials supplied by Neo Labs are intended exclusively for qualified in vitro and laboratory research. They are not for human consumption, clinical use, or veterinary application. Researchers are responsible for compliance with all applicable institutional and regulatory requirements.

Selected References

• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab.
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab.
• Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med.
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab.